Antineutrophil Cytoplasmic Antibodies Testing in a Large Cohort of Unselected Greek Patients

Table 3

Relationship between the results of ANCA testing and clinical diagnoses.

Diseases		p-ANCA	c-ANCA	x-ANCA	IIF (−)/ELISA (+)	Anti-MPO (+)	Anti-PR3 (+)	Total (N)
MPA	N	45	4	6	6	46	10	61
	%	73.8	6.6	9.8	9.8	75.4	16.4
WG	N	6	34	1	5	4	40	46
	%	13.0	73.9	2.2	10.9	8.7	87
CSS	N	4	0	2	0	6	0	6
	%	66.7	0.0	33.3	0.0	100	0.0
CTD	N	97	2	31	2	9	1	132
	%	73.5	1.5	23.5	1.5	6.8	0.7
GD	N	67	10	40	0	1	8	117
	%	57.3	8.5	34.2	0.0	17.9	7.7
Other vasculitides	N	27	1	11	0	7	3	39
	%	69.2	2.6	28.2	0.0	5.6	0.0
Infections	N	23	1	12	0	2	0	36
	%	63.9	2.8	33.3	0.0	5.6	0.0
ND	N	23	1	9	0	0	0	33
	%	69.7	3.0	27.3	0.0	0.0	0.0
Malignancies	N	21	1	9	0	1	0	31
	%	67.7	3.3	29.0	0.0	3.3	0.0
RD	N	18	0	4	0	2	0	22
	%	81.8	0.0	18.2	0.0	9.0	0.0
Medication	N	10	0	5	0	0	0	15
	%	66.7	0.0	33.3	0.0	0.0	0.0
Miscellaneous disorders	N	5	2	6	1	0	1	14
	%	35.7	14.3	42.9	7.1	0.0	7.1
Undefined diagnosis	N	63	4	39	3	2	3	109
	%	57.8	3.7	35.8	2.7	1.8	2.7

MPA: microscopic polyangiitis, WG: Wegener’s granulomatosis, CSS: Churg-Strauss syndrome, CTD: connective tissue diseases, GD: gastrointestinal diseases, ND: neurological diseases, RD: renal diseases.